Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zervimesine · CT-1812

Small molecule · developed by Cognition Therapeutics

Phase 2 Most advanced trial

CGTX Developer

3 Registered trials

What is Zervimesine?

Zervimesine (CT1812) is an orally dosed agent given once daily.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CT-1812, Study Drug Active, Active Comparator CT1812
Drug type: Small molecule
Therapy area: Neurology, Ophthalmology
Developer: Cognition Therapeutics (CGTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 0661V34NTV

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05531656	Phase 2	Early Alzheimer's Disease	Active not recruiting	CGTX
NCT05893537	Phase 2	Age-Related Macular Degeneration	Terminated	CGTX
NCT06961760	N/A	Dementia With Lewy Bodies	No longer available	CGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Alzheimer's DiseaseAge-Related Macular DegenerationDementia With Lewy Bodies

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CGTX page.

Follow CGTX, the company behind Zervimesine

See CGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z